The possible antianginal effect of allopurinol in vasopressin-induced ischemic model in rats

Saudi Pharmaceutical Journal

Volumn 23, Issue 5, 2015, Pages 487-498

  Al Zahrani, Yahya A ^a   Al Harthi, Sameer E ^a,b   Khan, Lateef M ^a   El Bassossy, Hani M ^a   Edris, Sherif M ^a,b   Sattar, Mai A Alim A ^a,c  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b Princess Al Jawhara Al Brahim Centre of Excellence in Research of Hereditary Disorders   (Saudi Arabia)

^c AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Allopurinol; Angina pectoris; ECG; ENOS expression; Vasopressin

Indexed keywords

ALLOPURINOL; AMLODIPINE; ANTIANGINA PECTORIS AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LIPID; MALONALDEHYDE; NITRATE; VASOPRESSIN;

ANGINA PECTORIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CELL FUNCTION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; ELECTROCARDIOGRAPHY; ENDOTHELIUM CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; ST SEGMENT DEPRESSION; SYSTOLIC BLOOD PRESSURE;

EID: 84943580032     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2014.12.001     Document Type: Article

References (52)

1. Alderman M.H. Uric acid and cardiovascular risk. Curr. Opin. Pharmacol. 2002, 2:126-130.
2. Barberi S., Mene P. Role of uric acid in hypertension and in the progression of chronic renal disease. G Ital Nefrol. 2006, 23(1):4-11. January-February.
3. Beckman J.S., Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am. J. Physiol. 1996, 271(5 Pt 1):C1424-C1437. (Review PubMed PMID: 8944624).
4. Beltrame J.F., Weekes A.J., Morgan C., Tavella R., Spertus J.A. The prevalence of weekly angina among patients with chronic stable angina in primary care practices: the Coronary Artery Disease in General Practice (CADENCE) Study. Arch. Intern. Med. 2009, 169:1491-1499.
5. Berry C.E., Hare J.M. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J. Physiol. 2004, 555:589-606.
6. De scheerder i.K., Van de kraay A.M., Lamers J.M., Koster J.F., De jong J.W., Serruys P.W. Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: potential mechanisms for free radical generation. Am. J. Cardiol. 1991, 68:392-395.
7. Desco m.C., Asensi M., Marquez R., Martinez-Valls J., Vento M., Pallardo F.V., Sastre J., Vina J. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 2002, 51:1118-1124.
8. Doehner W., Schoene N., Rauchhaus M., Leyva-Leon F., Pavitt d.V., Reaveley D.A., Schuler G., Coats A.J., Anker S.D., Hambrecht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002, 105:2619-2624.
9. Dyer A.R., Liu K., Walsh M., Kiefe C., Jacobs D.R., Bild D.E. Ten-year incidence of elevated blood pressure and its predictors: the CARDIA study Coronary Artery Risk Development in (Young) Adults. J. Hum. Hypertens. 1999, 13:13-21.
10. Ekelund U.e., Harrison R.w., Shokek O. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ. Res. 1999, 85:437-445.
11. El Solh A.A., Saliba R., Bosinski T., Grant B.J., Berbary E., Miller N. Allopurinol improves endothelial function in sleep apnoea: a randomised controlled study. Eur. Respir. J. 2006, 27:997-1002.
12. Elion g.B. Enzymatic and metabolic studies with allopurinol. Ann. Rheum. Dis. 1966, 25:608-614.
13. Eskurza I., Kahn Z.D., Seals D.R. Xanthine oxidase does not contribute to impaired peripheral conduit artery endothelium-dependent dilatation with ageing. J. Physiol. 2006, 571:661-668.
14. Feig D.I., Soletsky B., Johnson R.J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008, 300:924-932.
15. Forman J.P., Choi H., Curhan G.C. Plasma uric acid level and risk for incident hypertension among men. J. Am. Soc. Nephrol. 2007, 18:287-292.
16. Fraker T.D., Fihn S.D., Gibbons R.J. 2007 Chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J. Am. Coll. Cardiol. 2007, 50:2264-2274.
17. Freireich E.J., Gehan E.A., Rall D.P., Schmidt l.H., Skipper h.E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 1966, 50:219-244.
18. George J., Struthers A.D. The role of urate and xanthine oxidase inhibitors in cardiovascular disease. Cardiovasc. Ther. 2008, 26:59-64.
19. Ginsberg M.H., Kozin F., O'malley M., Mccarty D.J. Release of platelet constituents by monosodium urate crystals. J. Clin. Invest. 1977, 60:999-1007.
20. Halcox J.P., Nour K.R., Zalos G., et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J. Am. Coll. Cardiol. 2002, 40:1232-1240.
21. Harrison R. Oxidoreductase: structure and function of xanthine. where are we now?. Free Radic. Biol. Med. 2002, 33:774-797.
22. Hille R., Massey V. Studies on the oxidative half-reaction of xanthine oxidase. J. Biol. Chem. 1981, 256:9090-9095.
23. Hirata Y., Miyai H., Mabuchi, Sasaki T., Maruyama H., Kase Y., Takeda S., Aburada M. Antianginal effects of lercanidipine or methacholine on the vasopressin induced anginal model in rats. Biol. Pharm. Bull. 2005, 28:811-816.
24. Ikeda J., Matsubara M., Yao K. Effects of benidipine in a rat model for experimental angina. Yakugaku Zasshi 2006, 126:1377-1381.
25. Jelic-Ivanovic Z., Memon L., Spasojevic-Kalimanovska V., Bogavac-Stanojevic N., Spasic S. Independent association of high serum uric acid concentration with angiographically defined coronary artery disease. Tohoku J. Exp. Med. 2007, 211:369-377.
26. Khan F., George J., Wong K., Mcswiggan S., Struthers A.d., Belch J.j. Allopurinol treatment reduces arterial wave reflection in stroke survivors. Cardiovasc. Ther. 2008, 26:247-252.
27. Knight C.J., Fox K.M. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Studies in Angina Research (CESAR) Investigators. Am. J. Cardiol. 1998, 81:133-136.
28. Laursen j.B., Somers M., Kurz S., Mccann L., Warnholtz A., Freeman B.A., Tarpey M., Fukai t., Harrison d.G. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001, 103:1282-1288.
29. Lockette W., Otsuka Y., Carretero O. The loss of endothelium-dependent vascular relaxation in hypertension. Hypertension 1986, 8. II61-6.
30. Mazzali M., Kanellis J.J., Han I., Feng I., Xia Y.Y., Chen Q., Kang D.H., Gordon K.I., Watanabe S., Nakagawa T., Lan H.Y., Johnson R.J. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am. J. Physiol. Renal. Physiol. 2002, 282:F991-F1007.
31. Mellin V., Isabelle M., Oudot A. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long- term allopurinol treatment initiated in established chronic heart failure. Eur. Heart J. 2005, 26:1544-1550.
32. Menard j.C., Giacomini E., Baligand C., Fromes Y., Carlier P.G. Non- invasive and quantitative evaluation of peripheral vascular resistances in rats by combined NMR measurements of perfusion and blood pressure using ASL and dynamic angiography. NMR Biomed. 2010, 23:188-195.
33. Noman A., Ang D.S., Ogston S., Lang C.C., Struthers A.D. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomized, placebo controlled crossover trial. Lancet 2010, 375:2161-2167.
34. Parmley l.F., Mufti a.G., Downey j.M. Allopurinol therapy of ischemic heart disease with infarct extension. Can. J. Cardiol. 1992, 8:280-286.
35. Rekhraj S., Gandy S.J., Szwejkowski B.R., Nadir M.A., Noman A., Houston J.G., Lang C.C., George J., Struthers A.D. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J. Am. Coll. Cardiol. 2013, 61(9):926-932. Mar 5.
36. Rousseau M.F., Pouleur H., Cocco G., Wolff a.A. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am. J. Cardiol. 2005, 95:311-316.
37. Saavedra W.F., Paolocci N., St.John M.E. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ. Res. 2002, 90:297-304.
38. Saito I., Saruta T., Kondo K., Nakamura R., Oguro T., Yamagami K., Ozawa Y., kato E. Serum uric acid and the renin-angiotensin system in hypertension. J. Am. Geriatr. Soc. 1978, 26:241-247.
39. Sasaki T., Maruyama H., Kase Y., Takeda S., Aburada M. Antianginal effects of lercanidipine on the vasopressin or methacholine induced anginal model in rats. Biol. Pharm. Bull. 2005, 28:811-816.
40. Sathisha K.R., Khanum S.A., Chandra J.N., Ayisha F., Balaji S., Marathe G.K., et al. Synthesis and xanthine oxidase inhibitory activity of 7-methyl-2-(phenoxymethyl)- 5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one derivatives. Bioorg. Med. Chem. 2011 Jan 1, 19(1):211-220.
41. Shelmadine B., Bowden R.G., Wilson R.L., Beavers D., Hartman J. The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study. Anadolu Kardiyol Derg 2009, 9:385-389.
42. Struthers A.D., Donnan P.T., Lindsay P., Mcnaughton D., Broomhall J., Macdonald T.M. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002, 87:229-234.
43. Stull l.B., Leppo m.K., Szweda L., Gao w.D., Marban E. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ. Res. 2004, 95:1005-1011.
44. Suliman M.E., Johnson R.J., García-López E., Qureshi A.R., Molinaei H., Carrero J.J., Heimbürger O., Bárány P., Axelsson J., Lindholm B., Stenvinkel P. J-shaped mortality relationship for uric acid in CKD. Am. J. Kidney Dis. 2006 Nov, 48(5):761-771.
45. Tardif J.C., Ponikowski P., Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4- month, randomized, placebo-controlled trial. Eur. Heart J. 2009, 30:540-548.
46. Thadani U., Smith W., Nash S., Bittar N., Glasser S., Narayan P., Stein r.A., Larkin S., Mazzu A., Tota R., Pomerantz K., Sundaresan P. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J. Am. Coll. Cardiol. 2002, 40:2006-2012.
47. Tseng C.H. Acid levels with peripheral arterial disease in Taiwanese patients with Type 2 diabetes Independent association of uric 46. Diabet. Med. 2004, 21:724-729.
48. Tsikas D. Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the L-arginine/nitric oxide area of research. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 851:51-70.
49. Vuppalanchi R., Juluri R., Bell L.N., Ghabril M., Kamendulis L., Klaunig J.E., et al. Oxidative stress in chronic liver disease: relationship between peripheral and hepatic measurements. Am. J. Med. Sci. 2011, 342(4):314-317. October.
50. Yamamoto S., Matsui K., Sasabe M., Ohashi N. Effect of an orally active Na+/H+ exchange inhibitor, SMP-300, on experimental angina and myocardial infarction models in rats. J. Cardiovasc. Pharmacol. 2002, 39:234-241.
51. Yiginer O., Ozcelik F., Inanc T., Aparci M., Ozmen N., Cingozbay b.Y., Kardesoglu E., Suleymanoglu S., Sener G., Cebeci B.S. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin. Res. Cardiol. 2008, 97:334-340.
52. Zhao C.X., Xu X., Cui Y., Wang P., Wei X., Yang S., Edin M.L., Zeldin D.C., Wang D.W. Increased endothelial nitric-oxide synthase expression reduces hypertension and hyperinsulinemia in fructose-treated rats. J. Pharmacol. Exp. Ther. 2009, 328:610-620.